Stomach Cancer Drug Fails: Amgen Halts Testing On Rilotumumab Due To Deaths Of Study Participants

November 24, 2014 7:58 PM

5 0

Amgen announced on Monday that it is stopping its clinical trials for an experimental drug called rilotumumab intended to treat patients with advanced stomach cancer due to the sudden increase of deaths among the study participants.

Amgen announced on Monday that it is stopping its clinical trials for an experimental drug called rilotumumab intended to treat patients with advanced stomach cancer due to the sudden increase of deaths among the study participants.

Also read: Ecuador exit polls: ruling-party candidate has clear lead but runoff in doubt

Read more

To category page

Loading...